• Company’s CapitalCube.com performs billions of computations and delivers comprehensive analysis on every listed stock in the world every day
• Comparables suggest huge upside potential
• Proprietary artificial intelligence technology applicable to any data-driven industry

Individual investors now have the ability to utilize algorithms and analytics that are similar to those employed by Wall Street behemoths. CapitalCube.com, the flagship product of artificial intelligence pioneer AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF), performs billions of computations and delivers comprehensive analysis on every listed stock in the world every day. AnalytixInsight’s cutting-edge financial portal provides on-demand fundamental research, portfolio evaluation and screening tools on over 50,000 global equities and North American ETFs. By providing accounting and earnings reports, in-depth analysis, peer-to-peer performance evaluations, dividend strength and AI-derived information about potential corporate actions like dividend changes or acquisitions, the platform gives investors ready access to real-time tools to help them make informed financial decisions. Amazingly, access to basic financial information on CapitalCube.com is free, with charges only for more detailed and complex analysis and analytics.

AnalytixInsight’s proprietary artificial intelligence technology looks for meaning in numbers and data, transforms the disparate information into plain English and delivers it as actionable insights. The technology is scalable and applicable to virtually any data-driven industry, including communications, health care, insurance and government. With such broad applications, AnalytixInsight has already achieved strategic inroads in fintech, blockchain and workflow analytics. The company’s subsidiaries include Euclides Technologies, which is focused on field service management software solutions to develop and integrate workforce management solutions for large global corporations. AnalytixInsight also has joint ownership in its other subsidiary, MarketWall, with Intesa Sanpaolo, Italy’s largest retail bank. It is expected that MarketWall will deploy its real-time stock trading and mobile banking app to the bank’s 12.6 million customers by year end.

Recently selected as one of the TSX Venture’s top 50 companies, AnalytixInsight begs comparison with others connected to the space. Not really an AI company and focused more on trading than analytics, stock-trading app Robinhood launched in 2013 to offer a platform for younger, less-wealthy users to start investing (http://ibn.fm/Bqfbm). Through its mobile app, Robinhood provides information, instruction and news feeds and offers zero fees on trades. Last year, it launched its primary revenue stream, a $10 per month service that allows users to make trades instantly as well as trade on margin. Most interestingly, the company completed a capital raise last year during which DST Global valued the company at an incredible $1.3 billion.

AnalytixInsight, including its proprietary technology and all of its subsidiaries, has a current market valuation of only around $30 million. If the company reaches the same $1.3 billion valuation, it would equate to over 40 times the current stock price. Savvy investors understand market comparables and are likely to further explore the enormous upside potential in AnalytixInsight.

For more information, visit the company’s website at www.AnalytixInsight.com

Let us hear your thoughts: AnalytixInsight Inc. Message Board

• Accredited testing of cannabis products is becoming a crucial health care initiative
• Cannabis testing regulations vary state-by-state where cannabis is legal
• EVIO testing labs provide quality control testing, advisory services to regulated cannabis industry
• Testing services offered nationwide, with eight labs in five states and expansion opportunities in another four states and Canada

EVIO, Inc. (OTCQB: EVIO), a health sciences company focused on analyzing cannabis, continues to move the bar higher and set the standard when it comes to testing cannabis in each of its laboratory settings in states where the highly regulated plant is now legal. Headquartered in Oregon, EVIO Labs specializes in testing cannabis and industrial hemp flower, extracts and infused products. Its laboratories offer a crucial selection of analytical tests that meet international standards and state-regulated testing guidelines. EVIO Labs recently expanded its testing capabilities with the addition of delta-8 THC to its analyte list for cannabinoid profiling.

Recent recalls of certain cannabis products (http://ibn.fm/RNT1c), prompted by the discovery of mold and other identifiable contaminants in the recalled items, show the dire need for quality laboratory testing services. While links between illness and tainted cannabis are not well documented, anecdotal accounts include worrisome stories about cannabis infected with mites, mold or yeast, or grown with potentially cancer-causing pesticides (http://ibn.fm/LD36b).

EVIO’s dedication to attaining the highest of accreditation standards is a key element of the company’s success and one that should matter most to cannabis consumers, who are often seeking relief from specific ailments. In fact, EVIO Labs Florida recently achieved ISO 17025 accreditation, becoming the first accredited cannabis testing lab in the state (http://ibn.fm/jzQ3o). This achievement, which marks the highest recognized quality standard in the world for calibration and testing laboratories, means that EVIO Labs Florida consistently produces precise and accurate tests that are implemented under a rigorous quality management system (http://ibn.fm/JeCVW).

Notably, EVIO Labs Colorado has also completed its ISO accreditation, representing an important step in expanding the company’s footprint in the lucrative Colorado cannabis market. The company’s laboratories in Southborough, Massachusetts, and Berkeley, California, are expected to attain ISO accreditation by the end of Q2 2018.

For consumers and state regulators alike, knowing that a laboratory meets the stringent certification requirements established by the International Organization for Standardization (“ISO”) offers an important distinction as more states begin to legalize cannabis and must set their own health and safety standards (http://ibn.fm/L9o6O). EVIO Labs is on track to open 18 cannabis testing laboratories by the end of 2018 at locations dotted around the United States. The company is evaluating lab opportunities in Canada as well, in addition to finalizing discussions for several regional service centers.

EVIO continues to build its core management team with the addition of Al Lustig as president and Ron Russak as vice president of operations. Lustig comes to EVIO from pharmaceutical giant Pfizer, where he built, led and helped manage many district, regional and national sales organizations. Lustig’s role at EVIO includes driving growth in new and existing markets, including international sales and operational strategies. Russak, who spent 17 years at Quest Diagnostics, will spearhead the growth and profitability of EVIO’s expanding portfolio of cannabis testing labs.

A recently released letter to shareholders (http://ibn.fm/30nwA) offers additional information on these important developments.

For more information, visit the company’s website at www.EVIOLabs.com

Let us hear your thoughts: EVIO, Inc. Message Board

• Reign Sapphire Corp. using a strong marketing strategy to offer conflict-free jewelry
• Quality customizable jewelry to preserve life’s best memories
• Finger on the pulse of millennials

Reign Sapphire Corp. (OTCQB: RGNP), headquartered in Beverly Hills, California, is an ethical and sustainable jewelry company with three niche brands: Reign Sapphire, Coordinates Collection and Le Bloc. The three brands offer unique, quality craftsmanship pieces designed to capture memories. They are sold through a commission-based affiliate program that utilizes influencers, email campaigns and promotions, as well as digital advertisement and events. The company works hard to ensure that it has its finger on the pulse of millennials, with a large following across social media for all three brands and a focus on e-commerce. The stores have a low footprint run from a retail app and virtual point of sale. Items selected are drop-shipped directly to the customer. This eliminates inventory expenses and high cost square footage, and it requires only part-time salespeople. The company is a member of the American Gem Trading Association and is committed to fair trade and ethical sourcing and processing of gemstones.

Reign Sapphires are mined in Australia, and the land from which they are taken is restored. These conflict-free, natural sapphires are procured directly from certified mines. Great respect is paid to the environment, the miners and the local people directly affected by the gem trade. The mined gem is processed, sorted, polished, and then cut by master artisans. The gems are finally sent to the U.S., where each piece of jewelry is individually crafted in Los Angeles for the customer. RGNP is about producing beautiful jewelry to commemorate memories, but also about preserving a clean supply chain.

The company’s Coordinates Collections was launched in August 2013. It was inspired by its globetrotting founder, Owen De Vries, who wanted to find a way to preserve memories of his travels. He developed a wearable memory, both beautiful and meaningful to the wearer. The brand’s adventurous spirit can be found on its blog, where it highlights various locations under the title ‘Coordinates Envy’. These carefully hand-crafted pieces go through a 21-day craftsmanship process during which each is fully inspected and given the time and attention to detail necessary to ensure quality.

Le Bloc is also a customizable jewelry line. Rather than focusing on gems or coordinates, Le Bloc uses whimsical building blocks engraved with letters for the consumer’s creativity. Names, hashtags, messages and more can be spelled out on necklaces, bracelets, and earrings.

These three brands under the company are strategic in marketing to millennials by being custom-made, conflict-free, sold direct-to-customer and supported by a rapidly growing social media following.

For more information, visit the company’s website at www.ReignSC.com

Let us hear your thoughts: Reign Sapphire Corp. Message Board

• Groundbreaking 3D imaging technology
• Device portability is a major advantage over current CT facilities
• Reduced exposure to radiation due to system’s enhanced speed and accuracy

Aligned with its broader focus of manufacturing and bringing disruptive medical imaging solutions to market, Imaging3, Inc. (OTCQB: IGNG) will be seeking FDA approval for its revolutionary 3D imaging device, the Dominion Volumetric Imaging SmartScan™ (DVIS). Using high-resolution fluoroscopy, the Dominion can be used as a reference for any current or new medical procedures and can replace several existing devices, such as a CT scanner, that are far more cumbersome.

The DVIS has several advantages:

• A 3D image, which can be viewed in CT-like slice through, is produced in one second
• Its mobility enables it to fit through any standard doorway
• It has multiple pivot points to facilitate minimal patient movement
• It does not require a shielded room
• It can be wheeled from the ER to the operating room
• It works on standard 120V wall outlet power

First developed a decade ago, this groundbreaking technology has the potential to transform the medical imaging industry, which is predicted to grow to almost $56 billion globally by 2025 (http://ibn.fm/AWJCH). The scanner developed by Imaging3 will produce 3D diagnostic images in Single 3D SafeScan and Continuous 3D Scan mode due to its unique O-ring design, and it is the only system in existence that can produce a combination of 2D, 3D and CT imagery in one device. The DVIS spins at a high velocity, being significantly faster and more accurate than conventional scanners, which greatly reduces the subject’s exposure to radiation. Additionally, the device uses technology that employs high-resolution fluoroscopy to view any part of the human body.

The portability of the DVIS is a major benefit, enabling it to perform the functions of several existing devices with significant cost savings for health care facilities. Portability in general is a major issue, especially in emergency rooms (ERs), where time can mean the difference between life and death. Triage staff will be able to use the Dominion to assess patients faster and reduce the risk of misdiagnosis.

Imaging3 is intent on developing devices that will change the face of medical diagnostics. The company’s diagnostic imaging system is multi-functional and can replace several existing devices. Besides resulting in considerable cost savings for medical facilities and health care centers, this device will be particularly attractive in countries which don’t have the health care budgets to support expensive CT equipment.

The DVIS could have a wide range of applications in the health care industry. It can be used by orthopedic surgeons to diagnose fractures and sprains without requiring the patient to move. The device can also be used to diagnose soft tissue problems and help with pain management or vascular issues. In addition to its multiple medical uses, the Dominion can be used in different industries that require fast and accurate imaging, such as agriculture, security, food, transportation and many more.

Imaging3 is currently preparing to pursue a 510K with the FDA for approval of the device. Software testing for the Dominion has already been completed, with hardware hazard testing, expected to take about three months, yet to be finalized, according to CEO John Hollister (http://ibn.fm/SjqWo).

The company plans to file in the first half of the year. In addition to seeking FDA approval, Imaging3 will explore other uses for its revolutionary device by assessing which of the many potential markets will be its primary target. At the same time, the company will work on developing a final product, with plans to start commercializing the device in the first quarter of 2019.

For more information, visit the company’s website at www.Imaging3.com

• Recreational marijuana set to be legalized in Canada in July 2018
• Choom™ is developing unique lifestyle brand and national retail footprint in new $8.7 billion-plus market
• Retail rollout strategy provides entrepreneurs opportunity to profit from coming bonanza

Entrepreneurs and businesspeople across Canada now have the opportunity to participate in the country’s lucrative new recreational marijuana market. Estimated to exceed $8.7 billion annually, recreational marijuana is set to be legalized in July of this year, and savvy business folks are looking for a piece of the cannabis pie. This is little wonder, since legal recreational marijuana dispensaries are expected generate more revenue per square foot than Whole Foods. With the recent announcement of its national retail dispensary rollout strategy, Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) is providing individual entrepreneurs the opportunity to capitalize on the expected business boom by registering for their own Choom™ store (http://ibn.fm/Vmadr). Given the immense opportunity, response should easily exceed expectations.

Choom™ is targeting nothing less than becoming the premier recreational cannabis brand in Canada. With its fully-integrated business model, the company aims to be the seed-to-sale market leader in reaching the Canadian cannabis consumer. Choom™ intends to become a leading Canadian cannabis grower and will be developing a chain of high-end branded retail cannabis dispensaries in strategic Canadian jurisdictions. Choom™ retail stores will provide discriminating cannabis consumers a cool, modern, stylish dispensary designed by the same team responsible for some of the most recognizable retail environments in Canada. Cultivating an exceptional consumer experience is an essential segment of Choom’s overarching retail distribution strategy. A strong retail identity and powerful branding will set Choom apart in the newly-launched national recreational cannabis market.

Choom™ is led by a successful, seasoned professional, president and CEO Chris Bogart, who has over two decades of international experience in business enterprises and capital markets. Commenting on the retail rollout in a recent news release, Bogart stated, “We’re inviting people to open a dispensary with a world class brand built exclusively for the recreational cannabis market. We’re encouraging entrepreneurs to join our family by registering for their own Choom™ store. Choom™ is using design and retail strategies that have worked successfully at some of the most profitable storefronts in the country. We are telling our Choom™ story with our stores and will elevate the concept of a high-quality product though our new retail environments, and we’re inviting others to join us.”

By cultivating an exceptional consumer experience and offering entrepreneurs across Canada the opportunity to profit from the coming cannabis bonanza, Choom™ could establish a significant national retail footprint and become a recognized leader in the Canadian recreational cannabis markets.

For more information, visit the company’s website at www.Choom.ca

Let us hear your thoughts: Choom Holdings Inc. Message Board

• Cobalt demand is linked to exponential growth in production of electric vehicles
• Cobalt is forecast to experience increased global demand over the next few decades
• Historic records from three First Cobalt mines show reserves of one million pounds of cobalt

Following the resounding success of its maiden drill program in Cobalt South, First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) announced on February 21, 2018, that it had commenced drilling in Cobalt North. The new program is centered on the historic Drummond, Kerr and Conisil mines within the Cobalt Camp mining region of northern Ontario, according to a company press release (http://ibn.fm/mbt0D). In the update, president and CEO of First Cobalt Trent Mell explained that, during the company’s first drill campaign, three distinct cobalt mineralized zones were identified in Cobalt South, and the company will follow up on the discovery. The second leg of the winter drill campaign, in Cobalt North, is based on a rich set of historical data with the company’s own field work to build a 3D geological model. “In Cobalt North, we have several opportunities to identify resources in different styles of mineralization that would not have been considered historically. We believe this program will increase our options to find new cobalt resources in the Camp,” Mell explained in the news release.

The company’s decision to begin drilling in Cobalt North was based on polymetallic mineralization found in muckpile grab samples. These yielded grades of up to 0.65 percent cobalt with 4,990 g/t silver and up to 1.79 percent copper with 56 g/t silver. Historic records from the Drummond, Kerr and Conisil mines show almost one million pounds of cobalt and more than 36 million ounces of silver. These records were from a time when silver was the main target mineral, but the global surge in demand for cobalt over the last few years has put the spotlight firmly on developing mining assets for this mineral.

Cobalt is a critical component of the lithium-ion batteries used to power mobile electronic devices and electric vehicles (EVs). Developments in the automotive industry have accelerated the production of EVs. With increasing commitment by the world’s nations to turning away from the use of fossil fuels in order to reduce harmful carbon emissions, several countries around the world have announced plans to phase in a complete ban on fossil fuel-powered vehicles over the next few decades. It is this industry sector that has caused a flood in demand for cobalt.

The Democratic Republic of the Congo (DRC) has traditionally provided the majority of the world’s cobalt. However, the DRC presents an ethical dilemma for cobalt producers because of the prevalence of child labor in its mines. In addition, the country is highly unstable politically, which makes it an investment risk. By making a strategic decision to focus its efforts on developing its Canadian mining interests, First Cobalt has altogether dodged these problems.

In 2017, First Cobalt merged with CobalTech and Cobalt One and now controls over 10,000 acres of land within the Cobalt Camp region for prospecting and development. This includes 50 past-producing mines, a mill and the only permitted refinery in North America capable of producing cobalt battery materials. Currently, the refinery is on care and maintenance, and it has been determined that the facility would benefit significantly from modification and upgrading to realize its full production potential. The company has identified this as a speedier and cheaper option than building an entirely new facility.

First Cobalt is exceptionally well placed to capitalize on the surge of interest in cobalt. Its drill programs are on track and producing excellent results, and, once its refinery is back online, the company has the potential to be one of the largest exploration companies and cobalt producers in the world.

For more information, visit the company’s website at http://ibn.fm/FTSSF

Let us hear your thoughts: First Cobalt Corp. Message Board

• A fintech company focused on next-generation B2B international solutions
• MoneyTrac Technology and GreenBox POS working to provide optimal payment technologies
• A global financial eco-system, top-tier banking institutions and high-level financial technology partnerships

Global Payout, Inc. (OTC: GOHE) is an innovative fintech company providing fully customized comprehensive payment solutions for both domestic and international organizations transferring funds throughout the world. The focus is on next-generation B2B solutions for automating international fund transfers, payments, billing and invoicing processes. The Global Reserve Platform (“GRP”) is the company’s offering for managing financial products. GRP provides blockchain technology within virtual currency markets such as bitcoin, is currently available in 26 foreign languages, performs currency exchanges worldwide and offers KYC-compliance for all account holders and merchants.

In a news release, Global Payout CEO James Hancock shared that GOHE’s primary targets for expansion include logistics, cryptocurrency and cannabis (http://ibn.fm/rZMmp). GOHE is working hard to transform, overhaul and digitize the massive and global logistics and supply chain industry. It is focused on optimizing efficiency for its customers and partners by creating strategic technological solutions.

MoneyTrac Technology, Inc. (“MTRAC”), a subsidiary of GOHE, has entered into an exclusive partnership with GreenBox POS, LLC (“GBOX”), a blockchain company, to provide strategic sales and marketing resources. MTRAC is set to launch GBOX services in the U.S., Canada and Mexico in April 2018. GBOX’s customized payment solutions, electronic modifications and custom-built blockchain kiosk machines fall in perfectly with MTRAC’s mission of ‘Banking the Unbankable’. Since 2009, Global Payout has developed and sought out comprehensive and customized prepaid payment solutions for their customers and partners worldwide. This JV Agreement with equity and exclusivity in sales and marketing between MTRAC and GBOX positions the company to continue offering the solutions needed to run businesses with optimum efficiency (http://ibn.fm/Pz2Ru).

GOHE’s aim is to deliver a global financial eco-system with top-tier banking institutions through high-level financial technology partnerships. From the beginning, it has been dedicated to developing technological software solutions that have positioned the company to now address the many different needs in a changing and growing global economy. GOHE is committed to leading the way in fintech solutions.

For more information, visit the company’s website at www.GlobalPayout.com

Let us hear your thoughts: Global Payout, Inc. Message Board

• Developing opioid alternative for pain treatment
• Well-positioned to capture market share as an opioid substitute
• Timely market entry as opioid abuse reduces U.S. life expectancy

Opioids are taking a toll on the nation. Data released by the Centers for Disease Control and Prevention (CDC) show that, for the second year in a row, life expectancy in the United States declined due to deaths from opioid overdoses. A major contributing factor to these alarming statistics has been the increasing appearance of synthetic opioid fentanyl. The drug is immensely powerful and is suspected to be the reason why many overdoses turn out to be fatal. Compounding the crisis is the double-headed problem that fentanyl, although manufactured and marketed legally, is also produced and distributed illegally. This duality offers a pernicious path to illicit use for patients introduced to prescription opioids for pain relief. Luckily, alternatives to pain management are under development. One such option will emanate from the proposed merger between Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. The combined entity’s proposed first product candidate, QRX001, is expected to be developed for the treatment of post-surgical pain.

The rising use of destructive opioids is reversing the gains eked out by advances in medical science. Since 1963, U.S. life expectancy has improved, as newer drugs and better procedures are keeping us alive for longer. However, owing to increasing reliance on opioids, that trend was reversed in 2015 and 2016. Drug overdoses have now surpassed heart disease as the leading cause of death for Americans under the age of 55, according to the New York Times (http://ibn.fm/y9Lo6), and fentanyl appears to be the chief malefactor.

Developed in Belgium in the late 1950s, fentanyl is a mighty medication with an analgesic potency that’s 80 times as high as that of morphine. It was introduced into medical practice as an anesthetic in the 1960s because of its effectiveness and, in different forms, remains in extensive use today. By the mid-1970s, illicit fentanyl had begun to appear alongside heroin and cocaine as the fare of drug traffickers. It is now eclipsing those narcotics as a source of concern because of its murderous track record. While the biological effects of fentanyl are indistinguishable from those of heroin, for example, newly developed illicit analogues may be hundreds of times as potent. As a result, the possibility of overdose for a fentanyl user is significantly increased. Moreover, the crisis may get worse. Fentanyl is now commonly being added to boost the effects of heroin and cocaine, and it may even be passed off as those substances.

These disturbing developments make the need for gentler alternatives to opioids more pressing. Despite the ravage they cause, their use continues to increase. Consequently, the U.S. opioid market, currently estimated at around $12 billion, is expected to continue growing at a CAGR of 4.6 percent until 2024 (http://ibn.fm/lin53).

Replacing just a fraction of that use with an option like QRX001 is likely to lift the dark cloud hanging over the nation by weakening the forces driving the opioid onslaught. QRX001, to be the lead drug candidate of the post-merger entity (Quoin Pharmaceuticals Inc.), is a single-use transdermal non-competitive NMDA receptor antagonist intended for the treatment of post-surgical pain. An N-Methyl-D-Aspartate (NMDA) receptor allows the transfer of electrical signals between the brain and the rest of the nervous system. An NMDA receptor antagonist is a drug that inhibits the ability of that NMDA receptor to accept signals, which is very useful when those signals are experienced as pain.

The highly differentiated nature of QRX001 could position it to capture a significant market share either as monotherapy or as a key component of effective multi-modal therapy. As a result, Quoin intends to apply for fast track status for QRX001.

The completion of the merger between Skinvisible and Quoin is subject to the negotiation of a definitive agreement and other customary closing conditions, including Quoin completing a financing round for clinical development.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

• Cannabis-infused chocolates and candies, such as gummies, will be manufactured using LXRP’s next-generation, patented technology to be sold in Canada and internationally, where permitted
• LXRP’s goal is to partner with manufacturers who provide best-in-class products to existing large consumer groups
• Licensing DehydraTECH™ is key to LXRP’s generation of revenue; LXRP aims to license its IP in all countries where its technology is patented or patent pending

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) continues to generate revenue from licensing its proprietary and patented technology DehydraTECH™, which is already patented in the U.S. and Australia. The company also has multiple patents pending in more than 40 countries globally.

Lexaria’s entry into a seven-year definitive licensing agreement with Cannfections Group, Inc. in Canada is a major step toward bringing its improved delivery methodologies to market (http://ibn.fm/F5w4w). DehydraTECH promotes healthier ingestion methods and lower overall dosing. Cannfections is expected to leverage the platform by manufacturing and marketing cannabis-infused chocolates and candies for the legalized adult market.

Cannfections contract manufactures chocolate retail products for several international and domestic chocolate brands. The company believes that the agreement should lead not only to new product entries for Canadian cannabis edibles, but to exports to international markets, where permitted. In addition, the agreement permits LXRP to offer other licensee partners the option of using Cannfection’s manufacturing expertise to produce cannabis-infused chocolates and gummies powered by DehydraTECH technology.

DehydraTECH has been shown to increase intestinal absorption rates and provide for more rapid delivery of active ingredients to the bloodstream. It also offers taste-masking benefits for orally-administered molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs and nicotine.

“By licensing our technology to Cannfections, Lexaria can now offer its commercial clients the expertise of one of Canada’s oldest and most established chocolatiers utilizing next-generation DehydraTECH technology,” Chris Bunka, CEO of Lexaria, stated in a news release. “This is a long term strategic relationship meant to offer technology, value and expertise to Licensed Producers wanting to offer the highest quality chocolate edibles available in Canada once permitted under Health Canada regulations.”

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Company committed to scientific validation of CBD efficacy
• Produces, markets and sells only the highest quality Full-Spectrum Hemp Oil containing CBD
• With new subsidiaries and acquisition, future is increasingly bright

Building on vast anecdotal and mounting scientific evidence, the market for cannabidiol (CBD) products is exploding across the globe. The discovery of the human endocannabinoid system in the 1990s has intensified research and validated many of the anecdotal reports of CBD effectiveness in treating a variety of physical ailments.

Seizing on the immense market opportunity and substantiating efficacy with science, Earth Science Tech, Inc. (OTC: ETST) is focused on the science, research and studies of its high grade hemp CBD oil as a nutraceutical and dietary supplement. Earth Science already markets and sells some of the highest quality and purity Full Spectrum Hemp Oil containing CBD available. The company’s products are formulated using superior supercritical CO2 cold liquid extraction, through which the cannabinoids are kept at the rawest state possible in order to maintain essential therapeutic properties.

Earth Science believes that science is the foundation for the future of not only its high grade hemp CBD oil and its array of products, but also the entire global CBD market. In a commitment to the underlying science, Earth Science has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high grade hemp CBD oil. Research has already indicated that Earth Science CBD nutritional and dietary supplement products are at the top in the industrial hemp space. The company is committed to providing the public with sound scientific research and up-to-date information on the progress of studies being done on its high grade hemp CBD products.

In 2017, Earth Science launched two new subsidiaries, KannaBidioid Inc., to manufacture and distribute vapes/e-liquids and gummy edibles, and Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent. The company also acquired Canna Inno Laboratories Inc., which will allow it access to the burgeoning Canadian market and government grants.

Earth Science’s multi-faceted, science-based approach to the development, manufacture and sale of high quality CBD products places the company in a unique and enviable position headed into 2018 and beyond. As Chief Science Officer Michel Aubé, PhD, stated in a January 3, 2018, press release (http://ibn.fm/E9RPh), “[W]e will clearly be recognized as a leader in cannabinoids research and other health science research arena. Our future is shining bright.”

For more information, visit the company’s website at www.EarthScienceTech.com